Could a simple antibiotic combo save lives after heart valve surgery?
NCT ID NCT07442357
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study will test whether giving an extra antibiotic during a heart valve replacement procedure (TAVI) can lower the chance of bloodstream infection or death within 6 months. About 2,000 patients in Denmark will take part. Half will get the standard antibiotic, and half will get the standard plus an extra one targeting a specific bacteria.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Beta-lactam antibiotic (e.g., ampicillin) plus cephalosporin
- What this could lead to
- If it works, this could point toward a better way to prevent serious infections after heart valve replacement, potentially saving lives.
- What could go wrong
- This trial hasn't started yet, and it's testing a small change in routine care. The benefit may be small or not exist, and adding antibiotics carries risks like allergic reactions or antibiotic resistance.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 1,986 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Jun 2026
An estimate. Start dates often move.
- Expected to finish
-
Jun 2029
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * All patients \> 18 years of age undergoing TAVI at sites in Denmark Exclusion Criteria: * Patients who do not want to participate and have chosen to "opt-out" of the trial
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Aortic valve stenosis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Copenhagen University Hospital, Rigshospitalet
Copenhagen, Denmark
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can aggressive blood pressure treatment slow aortic valve disease?
- Why do animal heart valves wear out? immune system under investigation
- One scan to rule them all? new CT aims to replace multiple heart tests
- Which heart valve design wins for small aortic openings?
- Can a less invasive valve replacement tame a failing aortic valve?
- Can a new heart valve match the safety of proven ones?